Neurology Medical News about Alzheimer Disease

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
Acta Neurologica Scandinavica, 09/28/09

Wiig EH et al. – AQT processing speed, ADAS–Cog, and MMSE measures proved stable during the second 6 months of treatment with AChEI.

Exclusive Author Commentary
Elisabeth H. Wiig Ph.D., 10/14/09

The clinical implications of this research appears related to the finding that AQT showed appropriate levels of stability, equal to those of ADAS-Cog, for measuring responsiveness to CNS medication for Alzheimer's disease (AD). This suggests that AQT may be used in clinical practice to differentiate responders and non-responders to CNS medication that affects the central executive that controls attention, memory and cognitive flexibility (i.e., set shifting). Such clinical applications may prove valid beyond AD and appropriate in the medical treatment of other executive function disorders (e.g., ADHD, Tourette Spectrum Syndrome). Future research and clinical applications should clarify these questions.

<< Previous
Anticoagulants and antiplatelet agents and the risk of...

Next >>
Elevated basal cortisol level predicts lower hippocampal volume...

Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09 Relevance Score: 71%

High Blood Pressure Likely in Alzheimers Offspring
MedLinePlus, 11/04/09 Relevance Score: 70%

Activated astrocytes: a therapeutic target in Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09 Relevance Score: 69%

Protective Role For Copper In Alzheimers Disease
ScienceDaily, 10/14/09 Relevance Score: 69%

All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease
Expert Review of Neurotherapeutics, 11/19/09 Relevance Score: 68%